Vir Bio (VIR) Stock Forecast, Price Target & Predictions
VIR Stock Forecast
Vir Bio stock forecast is as follows: an average price target of $26.60 (represents a 235.44% upside from VIR’s last price of $7.93) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
VIR Price Target
The average price target for Vir Bio (VIR) is $26.60 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $35.00 to $15.00. This represents a potential 235.44% upside from VIR's last price of $7.93.
VIR Analyst Ratings
According to 10 Wall Street analysts, Vir Bio's rating consensus is 'Buy'. The analyst rating breakdown for VIR stock is 0 'Strong Buy' (0.00%), 7 'Buy' (70.00%), 3 'Hold' (30.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vir Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 02, 2024 | Gena Wang | Barclays | $28.00 | $9.73 | 187.77% | 253.09% |
| Jun 05, 2024 | Michael Ulz | Morgan Stanley | $15.00 | $12.66 | 18.48% | 89.16% |
| May 21, 2024 | Gena Wang | Barclays | $27.00 | $9.69 | 178.64% | 240.48% |
| Feb 21, 2023 | Paul Choi | Goldman Sachs | $28.38 | $25.74 | 10.26% | 257.88% |
| May 06, 2022 | Joseph Stringer | Needham | $35.00 | $21.87 | 60.04% | 341.36% |
The latest Vir Bio stock forecast, released on Aug 02, 2024 by Gena Wang from Barclays, set a price target of $28.00, which represents a 187.77% increase from the stock price at the time of the forecast ($9.73), and a 253.09% increase from VIR last price ($7.93).
Vir Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 3 |
| Avg Price Target | - | $28.00 | $23.33 |
| Last Closing Price | $7.93 | $7.93 | $7.93 |
| Upside/Downside | -100.00% | 253.09% | 194.20% |
In the current month, the average price target of Vir Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vir Bio's last price of $7.93. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 02, 2024 | Needham | Buy | Buy | Hold |
| Aug 02, 2024 | Barclays | Overweight | Overweight | Hold |
| Jun 05, 2024 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jun 05, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 21, 2024 | Barclays | Overweight | Overweight | Hold |
| May 07, 2024 | Needham | Buy | Buy | Hold |
| Mar 15, 2024 | H.C. Wainwright | Underperform | Underperform | Hold |
| Mar 15, 2024 | J.P. Morgan | Buy | Buy | Hold |
| Sep 08, 2023 | Bank of America Securities | - | Neutral | Downgrade |
| Feb 23, 2023 | Goldman Sachs | Buy | Buy | Hold |
Vir Bio's last stock rating was published by Needham on Aug 02, 2024. The company gave VIR a "Buy" rating, the same as its previous rate.
Vir Bio Financial Forecast
Vir Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $56.29M | $2.64M | $3.80M | $46.71M | $21.79M | $371.43M | - | $1.23B | $812.75M | $103.62M | $177.07M | $1.98M | $76.37K | $1.93M | $66.99M | $5.72M | $980.00K | $1.40M |
| Avg Forecast | $18.40M | $18.40M | $19.08M | $24.48M | $8.60M | $5.54M | $7.53M | $11.71M | $11.18M | $8.71M | $22.39M | $50.15M | $149.61M | $114.22M | $200.72M | $811.05M | $622.96M | $138.25M | $84.56M | $98.64M | $4.81M | $11.01M | $3.90M | $2.90M | $2.57M | $3.75M |
| High Forecast | $18.40M | $18.40M | $19.08M | $24.48M | $8.60M | $13.68M | $7.53M | $11.71M | $34.10M | $17.70M | $22.39M | $50.15M | $149.61M | $114.22M | $200.72M | $2.02B | $1.55B | $344.68M | $210.83M | $245.93M | $12.00M | $27.44M | $9.71M | $7.23M | $6.40M | $9.36M |
| Low Forecast | $18.40M | $18.40M | $19.08M | $24.48M | $8.60M | $1.39M | $7.53M | $11.71M | $692.44K | $4.25M | $22.39M | $50.15M | $149.61M | $114.22M | $200.72M | $408.36M | $313.66M | $69.61M | $42.58M | $49.67M | $2.42M | $5.54M | $1.96M | $1.46M | $1.29M | $1.89M |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| Surprise % | - | - | - | - | - | - | - | - | 5.04% | 0.30% | 0.17% | 0.93% | 0.15% | 3.25% | - | 1.52% | 1.30% | 0.75% | 2.09% | 0.02% | 0.02% | 0.18% | 17.20% | 1.97% | 0.38% | 0.37% |
Vir Bio's average Quarter revenue forecast for Mar 24 based on 2 analysts is $11.71M, with a low forecast of $11.71M, and a high forecast of $11.71M. VIR's average Quarter revenue forecast represents a -79.19% decrease compared to the company's last Quarter revenue of $56.29M (Dec 23).
Vir Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| EBITDA | - | - | - | - | - | - | - | - | $-114.87M | $-186.73M | $-215.19M | $-130.27M | $-159.38M | $208.55M | - | $1.11B | $547.41M | $112.25M | $63.27M | $-167.31M | $1.34M | $-83.16M | $-29.75M | $-75.92M | $-62.46M | $-47.12M |
| Avg Forecast | $-7.88M | $-7.88M | $-8.18M | $-10.49M | $-3.69M | $-2.37M | $-3.22M | $-527.51M | $-4.79M | $-3.73M | $-9.59M | $-564.18M | $-64.11M | $-48.94M | $-86.01M | $-603.40M | $388.95M | $-59.24M | $-36.24M | $-645.35M | $1.09M | $-73.46M | $-41.90M | $-50.13M | $-1.10M | $-35.82M |
| High Forecast | $-7.88M | $-7.88M | $-8.18M | $-10.49M | $-3.69M | $-596.95K | $-3.22M | $-422.01M | $-296.71K | $-1.82M | $-9.59M | $-451.34M | $-64.11M | $-48.94M | $-86.01M | $-482.72M | $466.74M | $-29.83M | $-18.24M | $-516.28M | $1.31M | $-58.76M | $-33.52M | $-40.11M | $-554.15K | $-28.65M |
| Low Forecast | $-7.88M | $-7.88M | $-8.18M | $-10.49M | $-3.69M | $-5.86M | $-3.22M | $-633.01M | $-14.61M | $-7.58M | $-9.59M | $-677.02M | $-64.11M | $-48.94M | $-86.01M | $-724.08M | $311.16M | $-147.70M | $-90.34M | $-774.42M | $872.03K | $-88.15M | $-50.27M | $-60.16M | $-2.74M | $-42.98M |
| Surprise % | - | - | - | - | - | - | - | - | 23.99% | 50.02% | 22.43% | 0.23% | 2.49% | -4.26% | - | -1.84% | 1.41% | -1.89% | -1.75% | 0.26% | 1.23% | 1.13% | 0.71% | 1.51% | 56.75% | 1.32% |
4 analysts predict VIR's average Quarter EBITDA for Dec 22 to be $-64.11M, with a high of $-64.11M and a low of $-64.11M. This is -130.74% lower than Vir Bio's previous annual EBITDA (Sep 22) of $208.55M.
Vir Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| Net Income | - | - | - | - | - | - | - | - | $-115.92M | $-163.41M | $-194.78M | $-140.96M | $-101.60M | $175.31M | - | $518.62M | $525.25M | $110.43M | $61.81M | $-168.91M | $-298.67 | $-84.61M | $-31.17M | $-77.24M | $-63.77M | $-48.31M |
| Avg Forecast | $-104.22M | $-128.74M | $-118.52M | $-112.62M | $-121.73M | $-143.39M | $-121.93M | $-532.55M | $-137.29M | $-164.42M | $-163.93M | $-569.57M | $-47.34M | $517.47M | $44.47M | $-609.17M | $373.21M | $470.42M | $148.90M | $-651.51M | $-242.00 | $-74.74M | $-43.89M | $-51.01M | $-89.85M | $-36.72M |
| High Forecast | $-104.22M | $-128.74M | $-118.52M | $-112.62M | $-121.73M | $-126.96M | $-121.93M | $-426.04M | $-118.02M | $-119.58M | $-163.93M | $-455.66M | $-47.34M | $620.96M | $44.47M | $-487.33M | $447.85M | $564.51M | $178.68M | $-521.21M | $-194.00 | $-59.79M | $-35.11M | $-40.81M | $-31.86M | $-29.38M |
| Low Forecast | $-104.22M | $-128.74M | $-118.52M | $-112.62M | $-121.73M | $-159.82M | $-121.93M | $-639.06M | $-154.15M | $-202.46M | $-163.93M | $-683.48M | $-47.34M | $413.97M | $44.47M | $-731.00M | $298.57M | $376.34M | $119.12M | $-781.82M | $-291.00 | $-89.69M | $-52.66M | $-61.21M | $-264.26M | $-44.07M |
| Surprise % | - | - | - | - | - | - | - | - | 0.84% | 0.99% | 1.19% | 0.25% | 2.15% | 0.34% | - | -0.85% | 1.41% | 0.23% | 0.42% | 0.26% | 1.23% | 1.13% | 0.71% | 1.51% | 0.71% | 1.32% |
Vir Bio's average Quarter net income forecast for Dec 22 is $-47.34M, with a range of $-47.34M to $-47.34M. VIR's average Quarter net income forecast represents a -127.00% decrease compared to the company's last Quarter net income of $175.31M (Sep 22).
Vir Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| SG&A | - | - | - | - | - | - | - | - | $43.09M | $41.08M | $47.10M | $46.78M | $38.74M | $43.17M | - | $38.26M | $55.78M | $50.50M | $28.78M | $25.74M | $70.94K | $18.86M | $16.39M | $12.65M | $11.81M | $9.22M |
| Avg Forecast | $206.84M | $206.84M | $214.52M | $275.22M | $96.71M | $62.28M | $84.59M | $131.66M | $125.62M | $97.93M | $251.66M | $563.73M | $1.68B | $1.28B | $2.26B | $92.83M | $39.63M | $1.55B | $69.33M | $1.11B | $57.76K | $123.72M | $43.79M | $32.60M | $28.87M | $42.20M |
| High Forecast | $206.84M | $206.84M | $214.52M | $275.22M | $96.71M | $153.73M | $84.59M | $131.66M | $383.27M | $198.92M | $251.66M | $563.73M | $1.68B | $1.28B | $2.26B | $111.39M | $47.56M | $3.87B | $83.19M | $2.76B | $69.31K | $308.46M | $109.18M | $81.27M | $71.98M | $105.21M |
| Low Forecast | $206.84M | $206.84M | $214.52M | $275.22M | $96.71M | $15.66M | $84.59M | $131.66M | $7.78M | $47.82M | $251.66M | $563.73M | $1.68B | $1.28B | $2.26B | $74.26M | $31.70M | $782.48M | $55.46M | $558.29M | $46.21K | $62.29M | $22.05M | $16.41M | $14.54M | $21.25M |
| Surprise % | - | - | - | - | - | - | - | - | 0.34% | 0.42% | 0.19% | 0.08% | 0.02% | 0.03% | - | 0.41% | 1.41% | 0.03% | 0.42% | 0.02% | 1.23% | 0.15% | 0.37% | 0.39% | 0.41% | 0.22% |
Vir Bio's average Quarter SG&A projection for Mar 24 is $131.66M, based on 2 Wall Street analysts, with a range of $131.66M to $131.66M. The forecast indicates a 205.54% rise compared to VIR last annual SG&A of $43.09M (Dec 23).
Vir Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 2 | 4 | 6 | 3 | 3 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 2 | 2 |
| EPS | - | - | - | - | - | - | - | - | $-0.00 | $-1.22 | $-1.45 | $-1.06 | $-0.76 | $1.32 | - | $3.93 | $4.01 | $0.85 | $0.48 | $-1.32 | $-0.00 | $-0.67 | $-0.27 | $-0.71 | $-0.69 | $-0.44 |
| Avg Forecast | $-0.77 | $-0.94 | $-0.87 | $-0.83 | $-0.89 | $-1.05 | $-0.89 | $-1.05 | $-1.01 | $-1.21 | $-1.20 | $-0.87 | $-0.35 | $-0.51 | $0.33 | $3.78 | $2.63 | $-0.05 | $-0.48 | $-0.21 | $-0.70 | $-0.60 | $-0.62 | $-0.53 | $-0.67 | $-0.69 |
| High Forecast | $-0.77 | $-0.94 | $-0.87 | $-0.83 | $-0.89 | $-0.93 | $-0.89 | $-1.05 | $-0.87 | $-0.88 | $-1.20 | $-0.87 | $-0.35 | $-0.51 | $0.33 | $11.12 | $7.72 | $-0.02 | $-0.17 | $-0.08 | $-0.25 | $-0.21 | $-0.22 | $-0.19 | $-0.24 | $-0.24 |
| Low Forecast | $-0.77 | $-0.94 | $-0.87 | $-0.83 | $-0.89 | $-1.17 | $-0.89 | $-1.05 | $-1.13 | $-1.49 | $-1.20 | $-0.87 | $-0.35 | $-0.51 | $0.33 | $1.34 | $0.93 | $-0.14 | $-1.40 | $-0.63 | $-2.07 | $-1.76 | $-1.81 | $-1.55 | $-1.96 | $-2.03 |
| Surprise % | - | - | - | - | - | - | - | - | 0.00% | 1.01% | 1.20% | 1.21% | 2.19% | -2.60% | - | 1.04% | 1.53% | -17.89% | -1.01% | 6.20% | 0.00% | 1.12% | 0.44% | 1.35% | 1.03% | 0.64% |
According to 4 Wall Street analysts, Vir Bio's projected average Quarter EPS for Dec 22 is $-0.35, with a low estimate of $-0.35 and a high estimate of $-0.35. This represents a -126.33% decrease compared to VIR previous annual EPS of $1.32 (Sep 22).
Vir Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CVAC | CureVac | $3.28 | $29.00 | 784.15% | Buy |
| VIR | Vir Bio | $7.93 | $26.60 | 235.44% | Buy |
| DAWN | Day One Biopharmaceuticals | $13.76 | $38.80 | 181.98% | Buy |
| AKRO | Akero Therapeutics | $26.64 | $46.00 | 72.67% | Buy |
| VKTX | Viking Therapeutics | $62.94 | $100.50 | 59.68% | Buy |
| TERN | Terns Pharmaceuticals | $9.63 | $14.25 | 47.98% | Buy |
| MDGL | Madrigal Pharmaceuticals | $233.36 | $315.75 | 35.31% | Buy |
| PTCT | PTC Therapeutics | $35.07 | $44.33 | 26.40% | Hold |
| BPMC | Blueprint Medicines | $86.51 | $101.50 | 17.33% | Buy |
| AMLX | Amylyx Pharmaceuticals | $2.92 | $3.33 | 14.04% | Buy |
| KRYS | Krystal Biotech | $189.26 | $191.00 | 0.92% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
VIR Forecast FAQ
Is Vir Bio a good buy?
Yes, according to 10 Wall Street analysts, Vir Bio (VIR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 70.00% of VIR's total ratings.
What is VIR's price target?
Vir Bio (VIR) average price target is $26.6 with a range of $15 to $35, implying a 235.44% from its last price of $7.93. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Vir Bio stock go up soon?
According to Wall Street analysts' prediction for VIR stock, the company can go up by 235.44% (from the last price of $7.93 to the average price target of $26.6), up by 341.36% based on the highest stock price target, and up by 89.16% based on the lowest stock price target.
Can Vir Bio stock reach $12?
VIR's average twelve months analyst stock price target of $26.6 supports the claim that Vir Bio can reach $12 in the near future.
What are Vir Bio's analysts' financial forecasts?
Vir Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $33.38M (high $41.52M, low $29.23M), average EBITDA is $-537M (high $-430M, low $-646M), average net income is $-920M (high $-797M, low $-1.043B), average SG&A $375.24M (high $466.69M, low $328.62M), and average EPS is $-3.892 (high $-3.772, low $-4.013). VIR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $80.37M (high $80.37M, low $80.37M), average EBITDA is $-34.438M (high $-34.438M, low $-34.438M), average net income is $-464M (high $-464M, low $-464M), average SG&A $903.41M (high $903.41M, low $903.41M), and average EPS is $-3.407 (high $-3.407, low $-3.407).
Did the VIR's actual financial results beat the analysts' financial forecasts?
Based on Vir Bio's last annual report (Dec 2023), the company's revenue was $86.18M, which missed the average analysts forecast of $92.42M by -6.76%. Apple's EBITDA was $-684M, beating the average prediction of $-582M by 17.52%. The company's net income was $-615M, missing the average estimation of $-1.035B by -40.59%. Apple's SG&A was $178.05M, missing the average forecast of $1.04B by -82.86%. Lastly, the company's EPS was $-0.0046, missing the average prediction of $-4.293 by -99.89%. In terms of the last quarterly report (Dec 2023), Vir Bio's revenue was $56.29M, beating the average analysts' forecast of $11.18M by 403.68%. The company's EBITDA was $-115M, beating the average prediction of $-4.789M by 2298.68%. Vir Bio's net income was $-116M, missing the average estimation of $-137M by -15.57%. The company's SG&A was $43.09M, missing the average forecast of $125.62M by -65.70%. Lastly, the company's EPS was $-0.0009, missing the average prediction of $-1.008 by -99.91%